A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib

The second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) alectinib and ceritinib are standard treatment options for patients with non–small cell lung cancer (NSCLC) positive for ALK fusion genes. However, almost all patients eventually develop resistance to these drug...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Makuuchi, Yosuke, Hayashi, Hidetoshi, Haratani, Koji, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Sakai, Kazuko, Shimizu, Shigeki, Ito, Akihiko, Nishio, Kazuto, Nakagawa, Kazuhiko
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955410/
https://ncbi.nlm.nih.gov/pubmed/29796191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25143
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller